Cited by 284Inflammatory Bowel DiseaseAdenosine and Purinergic SignalingBiochemical and Molecular Research

CD39 deletion exacerbates experimental murine colitis and human polymorphisms increase susceptibility to inflammatory bowel disease

Open access
Friedman, David J., Künzli, Beat M., A-Rahim, Yousif I., Sevigny, Jean, Berberat, Pascal O., Enjyoji, Keiichi, Csizmadia, Eva, Friess, Helmut +1 more·2009·Proceedings of the National Academy of Sciences

Abstract

CD39/ENTPD1 hydrolyzes proinflammatory nucleotides to generate adenosine. As purinergic mediators have been implicated in intestinal inflammation, we hypothesized that CD39 might protect against inflammatory bowel disease. We studied these possibilities in a mouse model of colitis using mice with global CD39 deletion. We then tested whether human genetic polymorphisms in the CD39 gene might influence susceptibility to Crohn's disease. We induced colitis in mice using Dextran Sodium Sulfate (DSS). Readouts included disease activity scores, histological evidence of injury, and markers of inflammatory activity. We used HapMap cell lines to find SNPs that tag for CD39 expression, and then compared the frequency of subjects with high vs. low CD39-expression genotypes in a case-control cohort for Crohn's disease. Mice null for CD39 were highly susceptible to DSS injury, with heterozygote mice showing an intermediate phenotype compared to wild type (WT). We identified a common SNP that tags CD39 mRNA expression levels in man. The SNP tagging low levels of CD39 expression was associated with increased susceptibility to Crohn's disease in a case-control cohort comprised of 1,748 Crohn's patients and 2,936 controls ( P = 0.005–0.0006). Our data indicate that CD39 deficiency exacerbates murine colitis and suggest that CD39 polymorphisms are associated with inflammatory bowel disease in humans.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1073/pnas.0902869106

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Individuals with reduced ability to transcribe CD39 due to a promoter polymorphism have better responses to TIV and VZV vaccination.

    “Consistent with these in vitro observations, individuals with reduced ability to transcribe CD39 due to a promoter polymorphism (Friedman et al., 2009) have better responses to TIV as well as VZV vaccination”

    From Successful and Maladaptive T Cell Aging (2017) · cites this paper as Friedman et al., 2009

  • In humans, polymorphisms of ENTPD1 are associated with IBD, and P2X7 expression is increased in the intestinal epithelium and lamina propria of IBD patients.

    “In humans, polymorphisms of ENTPD1 were shown to be associated with IBD, and expression of P2X7 was increased in the intestinal epithelium and lamina propria of IBD patients (Friedman et al., 2009; Neves et al., 2014).”
  • Entpd1−/− mice, which cannot remove extracellular ATP through this mechanism, were highly susceptible to experimental colitis.

    “Entpd1−/− mice, which cannot remove extracellular ATP through this mechanism, where highly susceptible to experimental colitis (Friedman et al., 2009).”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Friedman, D. J., Künzli, B. M., A-Rahim, Y. I., Sevigny, J., Berberat, P. O., Enjyoji, K., Csizmadia, E., Friess, H., & Robson, S. C.
Affiliations
  • Beth Israel Deaconess Medical Center (US)
  • University of Hawaiʻi at Mānoa (US)
  • Transplantation Center and Gastroenterology Division, Beth Israel Deaconess Medical Center, Harvard University, 330 Brookline Avenue, Boston, MA 02215;
  • Technical University of Munich (DE)
Venue
Proceedings of the National Academy of Sciences
Published
2009-09-29
Volume
106
Issue
39
Pages
16788-16793
ISSN
  • 0027-8424 (ISSN-L)
  • 1091-6490
OpenAlex
W2163178183
Cited by
284
References
40
Citations by year
2026: 8 · 2025: 14 · 2024: 12 · 2023: 14 · 2022: 23 · 2021: 15 · 2020: 25 · 2019: 23 · 2018: 15 · 2017: 20 · 2016: 18 · 2015: 20 · 2014: 20 · 2013: 15 · 2012: 21
FWCI
8.19
Type
journal article
Language
en
Open access
Locations
  • Proceedings of the National Academy of Sciences (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • mediaTUM (Technical University of Munich) (submittedVersion)
Funders
  • Howard Hughes Medical Institute
  • Wellcome Trust
  • National Institutes of Health (5p01hl076540-10)
  • National Heart, Lung, and Blood Institute (HL-57307, HL63972, HL 076540, R01HL094400, P01 HL-076540, R01HL057307, R01HL063972)
  • National Institute of Diabetes and Digestive and Kidney Diseases (K08DK076868)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Inflammatory Bowel Disease
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Physiology › Adenosine and Purinergic Signaling
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Biochemical and Molecular Research
Keywords
CD39, adenosine, purinergic signaling, inflammatory bowel disease, Crohn's disease, colitis, DSS-induced colitis, genetic polymorphism, single nucleotide polymorphisms, genetic susceptibility, nucleotide hydrolysis
MeSH terms
Animals, Apyrase, Colitis, Crohn Disease, Disease Models, Animal, Genotype, Humans, Mice, Inbred C57BL, Polymorphism, Genetic, RNA, Messenger, Inflammatory Bowel Diseases, Antigens, CD, Sequence Deletion, Genetic Predisposition to Disease, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review